Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis

ObjectivesAnti-Ro52 autoantibodies are associated with more severe interstitial lung disease (ILD) in adult myositis patients with antiaminoacyl transfer (t)RNA synthetase autoantibodies. However, few studies have examined anti-Ro52 autoantibodies in juvenile myositis. The purpose of this study was...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 78; no. 7; pp. 988 - 995
Main Authors Sabbagh, Sara, Pinal-Fernandez, Iago, Kishi, Takayuki, Targoff, Ira N, Miller, Frederick W, Rider, Lisa G, Mammen, Andrew Lee
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd and European League Against Rheumatism 01.07.2019
BMJ Publishing Group LTD
Subjects
anti-ro52 autoantibodies
Arthritis
Autoantibodies
Autoantibodies - blood
Autoantibodies - immunology
Autoimmune diseases
Biopsy
Child
Connective tissue diseases
Dermatomyositis
Dermatomyositis - blood
Dermatomyositis - immunology
Enzyme-linked immunosorbent assay
Female
Humans
Illnesses
Inflammatory diseases
interstitial lung disease
juvenile idiopathic inflammatory myopathies
Laboratories
Lung diseases
Lung Diseases, Interstitial - epidemiology
Lung Diseases, Interstitial - immunology
Male
Medical prognosis
Medical records
Musculoskeletal diseases
Myositis
Myositis - blood
Myositis - immunology
myositis associated autoantibodies
Patients
Polymyositis
Prevalence
Remission
Rheumatology
Ribonucleic acid
Ribonucleoproteins - immunology
RNA
tRNA
myositis associated autoantibodies
interstitial lung disease
anti-ro52 autoantibodies
myositis
juvenile idiopathic inflammatory myopathies
Online AccessGet full text

Cover

More Information
Summary:ObjectivesAnti-Ro52 autoantibodies are associated with more severe interstitial lung disease (ILD) in adult myositis patients with antiaminoacyl transfer (t)RNA synthetase autoantibodies. However, few studies have examined anti-Ro52 autoantibodies in juvenile myositis. The purpose of this study was to define the prevalence and clinical features associated with anti-Ro52 autoantibodies in a large cohort of patients with juvenile myositis.MethodsWe screened sera from 302 patients with juvenile dermatomyositis (JDM), 25 patients with juvenile polymyositis (JPM) and 44 patients with juvenile connective tissue disease–myositis overlap (JCTM) for anti-Ro52 autoantibodies by ELISA. Clinical characteristics were compared between myositis patients with and without anti-Ro52 autoantibodies.ResultsAnti-Ro52 autoantibodies were found in 14% patients with JDM, 12% with JPM and 18% with JCTM. Anti-Ro52 autoantibodies were more frequent in patients with antiaminoacyl tRNA synthetase (64%, p<0.001) and anti-MDA5 (31%, p<0.05) autoantibodies. After controlling for the presence of myositis-specific autoantibodies, anti-Ro52 autoantibodies were associated with the presence of ILD (36% vs 4%, p<0.001). Disease course was more frequently chronic, remission was less common, and an increased number of medications was received in anti-Ro52 positive patients.ConclusionsAnti-Ro52 autoantibodies are present in 14% of patients with juvenile myositis and are strongly associated with anti-MDA5 and antiaminoacyl tRNA synthetase autoantibodies. In all patients with juvenile myositis, those with anti-Ro52 autoantibodies were more likely to have ILD. Furthermore, patients with anti-Ro52 autoantibodies have more severe disease and a poorer prognosis.
Bibliography:Members of the Childhood Myositis Heterogeneity Collaborative Study Group who contributed to this project
These authors contributed equally to this project.
Bita Arabshahi, Lilliana Barillas-Arias, Mara Becker, April Bingham, Ruy Carrasco, Victoria Cartwright, Rodolfo Curiel, Marietta M. DeGuzman, Barbara Anne Eberhard, Barbara S. Edelheit, Terri Finkel, Stephen W. George, Ellen A. Goldmuntz, William Hannan, Michael Henrickson, Adam M. Huber, Anna Jansen, James Jarvis, Lawrence Jung, Ildy M. Katona, Steven J. Klein, W Patrick Knibbe, Bianca A. Lang, Carol B. Lindsley, Gulnara Mamyrova, Linda Myers, Stephen R. Mitchell, Kabita Nanda, Terrance P. O’Hanlon, Murray H. Passo, Maria D. Perez, Donald A. Person, Linda I. Ray, Rafael F. Rivas-Chacon, Tova Ronis, Deborah Rothman, Adam Schiffenbauer, Bracha Shaham, David Sherry, Abigail Smukler, Matthew L. Stoll, Sangeeta H. Sule, Scott A. Vogelgesang, Rita Volochayev, Jennifer C. Wargula, Pamela Weiss.
CONTRIBUTORSHIP: SA, IPF, LGR, and ALM conceived the work. LGR and INT acquired, analyzed and interpreted data. SA, IPF, and TK analyzed and interpreted data. FWM interpreted data. SA, IPF, and ALM drafted the work and revised it critically for important intellectual content. TK, IPF, FWM, and LGR revised the work for critically important intellectual content. SA, IPF, LGR, ALM, INT, TK, and FWM approved of the final version of the manuscript. All members of the Childhood Myositis Heterogeneity Collaborative Study Group contributed by (a) providing substantial contributions to the acquisition of data; (b) revising the work critically for important intellectual content; and (c) providing final approval of the version published.
ISSN:0003-4967
1468-2060
DOI:10.1136/annrheumdis-2018-215004